Amgen(US:AMGN) Yahoo Finance·2025-10-16 05:59Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as one of the 11 Defensive Healthcare Dividend Stocks to consider for investment [1] - Oppenheimer has reaffirmed an Outperform rating for Amgen with a price target of $380, citing strong revenue growth and successful trial results [3] Financial Performance - Amgen has demonstrated reliable dividend growth, having increased its payouts for 14 consecutive years, with a current dividend yield of 3.23% as of October 14 [5] Clinical Developments - The VESALIUS-CV trial achieved its primary goals, indicating that the addition of Repatha to standard lipid-lowering treatments significantly reduces cardiovascular events in high-risk patients without prior heart attack or stroke [3][4] - The trial results were both statistically and clinically significant, meeting all key composite endpoints, with no new safety issues reported [4] Market Strategy - Amgen has entered the direct-to-consumer market, planning to sell Repatha at a cash price that is 60% lower than its current list price, aligning with industry efforts to enhance medication accessibility amid political pressure to lower drug costs in the U.S. [4]